Form 4: Sarepta Therapeutics Director Stephen Mayo Reports Stock and Option Transactions

Director Stephen Mayo reports acquisition of restricted stock units and stock options in Sarepta Therapeutics.

Summary

• On March 1, 2024, Stephen Mayo, a director of Sarepta Therapeutics, acquired 1,846 shares of common stock through restricted stock units (RSUs) at a price of $0.
• These RSUs will vest in full on March 1, 2025.
• On the same date, Mayo also acquired stock options for 3,679 shares of common stock with an exercise price of $128.67, exercisable from March 1, 2025, and expiring on March 1, 2034.
• Following these transactions, Mayo directly owns 9,756 shares of common stock and 3,679 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock and option transactions by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides information for investors to interpret.

Positives

• The acquisition of RSUs and stock options by a director could be interpreted as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock and options as a sign of confidence in the company's future prospects.

Key Dates